Mackenzie Financial Corp increased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 419.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,736,434 shares of the company’s stock after purchasing an additional 1,402,230 shares during the period. Mackenzie Financial Corp owned 0.17% of Teva Pharmaceutical Industries worth $30,561,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of the stock. Kornitzer Capital Management Inc. KS lifted its position in Teva Pharmaceutical Industries by 19.8% during the second quarter. Kornitzer Capital Management Inc. KS now owns 11,320 shares of the company’s stock worth $376,000 after acquiring an additional 1,870 shares during the last quarter. CIBC Asset Management Inc lifted its position in Teva Pharmaceutical Industries by 0.3% during the second quarter. CIBC Asset Management Inc now owns 65,534 shares of the company’s stock worth $2,177,000 after acquiring an additional 178 shares during the last quarter. Ingalls & Snyder LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $272,000. Korea Investment CORP acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $7,112,000. Finally, IFP Advisors Inc lifted its position in Teva Pharmaceutical Industries by 3.8% during the second quarter. IFP Advisors Inc now owns 12,629 shares of the company’s stock worth $420,000 after acquiring an additional 459 shares during the last quarter. Institutional investors and hedge funds own 52.05% of the company’s stock.

Several equities research analysts have issued reports on TEVA shares. BidaskClub downgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Credit Suisse Group restated an “outperform” rating and set a $39.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Wednesday, August 9th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective (down from $31.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, August 9th. Jefferies Group restated a “hold” rating and set a $26.00 price objective (down from $33.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, August 9th. Finally, Deutsche Bank restated a “buy” rating and set a $28.00 price objective (down from $43.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, August 9th. Seven research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $21.65.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up $0.01 during midday trading on Wednesday, hitting $15.06. 10,220,100 shares of the stock were exchanged, compared to its average volume of 15,647,090. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Limited has a 52 week low of $10.85 and a 52 week high of $38.31. The firm has a market capitalization of $15,290.80, a P/E ratio of 3.48 and a beta of 0.55.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a $0.085 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a yield of 2.26%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is -12.10%.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Limited (TEVA) Shares Bought by Mackenzie Financial Corp” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-shares-bought-by-mackenzie-financial-corp/1748019.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.